Get Skinny

The Medications · November 7, 2026 · 7 min · By Maeve Castellucci

Wegovy pill vs compounded semaglutide: what actually changes when you switch from a vial to a tablet

The Wegovy pill is the same molecule as compounded semaglutide, but almost nothing else about the two is the same. The tablet needs a dose ten times larger than the shot because the gut absorbs only a sliver of it, and that one fact explains its strict morning ritual, its price, and why it is not a simple swap.

Single white tablet beside a small glass of water on a pale counter in soft morning window light

A lot of people on compounded semaglutide are asking the same question right now: is the Wegovy pill better? The worry behind it is usually quality. You have read the headlines about dosing errors and warning letters, a daily tablet from a brand name manufacturer now exists, and the self pay price is close to what some telehealth programs charge for a compounded vial. So should you switch?

The short answer is that the Wegovy pill and compounded semaglutide contain the same molecule and almost nothing else in common. One is an FDA approved product with a known dose in every tablet and a large trial behind it. The other is a pharmacy preparation that the FDA has never reviewed. But the pill also comes with rules the injection never asked of you, and if you ignore them it simply does not work.

The original element in this piece is a seven question switch audit. It is a sequence you can run tonight, with your current vial and your daily routine in front of you, to see whether moving to the tablet makes sense, what will change in your week, and what to ask your prescriber before you stop the injection. We have not seen the switch decision broken down this way anywhere else.

What the Wegovy pill is, and why the dose looks so high

The Wegovy pill is oral semaglutide at a maintenance dose of 25 mg once a day, approved by the FDA for chronic weight management in December 2025. It climbs through 1.5, 4 and 9 mg tablets before reaching 25 mg, the same low and slow logic we explain in our piece on why your starting dose is not your treatment dose.

If you have been injecting 2.4 mg a week, a 25 mg daily tablet sounds like an enormous jump. It is not. Semaglutide is a protein-like molecule that stomach acid and digestive enzymes normally destroy. The tablet includes an absorption enhancer that protects a small amount of the drug long enough to cross the stomach lining, but only a small fraction of each tablet ever reaches your bloodstream. That is why the oral dose has to be roughly ten times larger per week than the injected one to land at a similar level in the blood.

This is the quotable part, and the reason the switch is not trivial: the same molecule behaves like a different drug depending on how it enters your body. The injection delivers almost all of its dose. The pill delivers a sliver, and how big that sliver is depends on what else is in your stomach.

Does the Wegovy pill work as well as the shot?

On the trial evidence, close to it. In OASIS 4, adults with obesity or overweight and at least one weight related condition, none with diabetes, took 25 mg of oral semaglutide or a placebo every day for 64 weeks alongside lifestyle support. The pill group lost an average of 13.6 percent of body weight, versus 2.2 percent on placebo (Wharton et al., NEJM 2025). Gastrointestinal side effects were common: 74 percent of the pill group reported them, versus 42 percent on placebo.

An earlier trial of a higher 50 mg oral dose found a 15.1 percent average loss over 68 weeks (Knop et al., Lancet 2023), and a 2026 indirect comparison that lined OASIS 4 up against STEP 1, the injectable 2.4 mg trial, concluded the two formulations deliver comparable weight loss, with a gap of about one percentage point that fell well inside the statistical uncertainty (Diabetes, Obesity and Metabolism 2026).

There is no such evidence for compounded semaglutide. Not weaker evidence; none. Compounded products are not studied in trials, and the FDA states plainly that it does not review them for safety, effectiveness or quality (FDA). Your compounded vial may be fine. The point is that nobody outside the pharmacy has checked.

Where compounded semaglutide actually goes wrong

The most documented harm is not contamination. It is dosing. A poison control center case series described patients who gave themselves tenfold overdoses of compounded semaglutide, partly because vials arrive with generic syringes and doses written in units or milliliters instead of milligrams (Lambson et al., JAPhA 2023). The FDA has issued its own alert on dosing errors with compounded injectable semaglutide, some serious enough to need hospital care.

The FDA also warns about salt forms. Semaglutide sodium and semaglutide acetate are different active ingredients from the semaglutide in approved products, and the agency says it knows of no lawful basis for compounding with them. If your label carries either word, you are not taking the molecule that was studied. Our guide to compounded versus brand semaglutide covers the rest, and our Wegovy generic name explainer includes a five question label check for sorting any product you have.

A tablet removes the dosing error problem almost entirely. Every 25 mg tablet holds 25 mg. There is nothing to draw up.

What the pill asks of you that the shot never did

The tablet has to be taken on an empty stomach, first thing in the morning, with no more than about four ounces of plain water, and then you wait at least 30 minutes before eating, drinking anything else or taking other medicines. Coffee counts. A multivitamin counts. Food or a full glass of water shrinks the sliver of drug that gets absorbed, so a sloppy morning is effectively a lower dose.

That matters if you take other morning medicines. Thyroid hormone, for instance, has its own empty stomach rule, and the two have to be sequenced with your prescriber's help. We cover how GLP-1 drugs change absorption of other pills in our absorption audit.

It also changes the rhythm of missed doses. Miss a weekly injection and you have a window to catch up. Miss a daily tablet and you simply take the next one the next morning. Seven chances a week to forget, but each one matters less.

The seven question switch audit

Run these in order and write your answers down. Bring the page to your prescriber.

Question one: what is in your vial? Read the label for the exact active ingredient. If it says semaglutide sodium or acetate, or names no pharmacy, that alone is a strong reason to move to an approved product, pill or pen.

Question two: what dose are you actually on in milligrams? Convert your units to milligrams with your pharmacist. Your prescriber needs this to decide where on the tablet ladder you start. Do not assume you can jump straight to 25 mg.

Question three: can you protect a 30 minute window every morning? If you leave the house in a rush, drink coffee in the car or take medicines on waking, be honest. A pill you take wrong is a weaker drug.

Question four: what else do you take in the morning? List every pill, supplement and drink. Anything with its own timing rule needs a plan.

Question five: how did you tolerate the injection? The pill's side effects in OASIS 4 looked like the shot's: nausea, diarrhea, constipation. If you were struggling on the injection, a different route will not erase that.

Question six: what will you pay? At launch, Novo Nordisk listed self pay prices of $149 a month for the starting dose and $299 a month for the 25 mg maintenance dose through NovoCare, with lower copays for some commercially insured patients. Prices have shifted during 2026, so confirm the current figure. Compare it to your all-in compounded cost, including program fees.

Question seven: is there a competing pill to consider? Eli Lilly's orforglipron, sold as Foundayo, was approved in April 2026. It is a different, non-peptide molecule that can be taken without the empty stomach ritual, though its average weight loss in trials was lower than oral semaglutide's. If question three was a no, ask about it.

If you answered yes to questions one and three and the price in question six is workable, the switch is usually worth discussing seriously.

What the studies do not tell you

No trial has studied people switching from compounded semaglutide to the pill. Every OASIS participant started from scratch. So nobody can tell you with data how much ground you might lose, if any, while you titrate up the tablet ladder, or whether your prescriber can safely start you higher. Those are judgment calls, and they are exactly why the switch should be planned rather than done the day the new box arrives.

The trials also measured people who took the tablet correctly under trial supervision. Real mornings are messier, and we do not yet have good data on how much real world adherence to the 30 minute rule erodes the result.

If you have tried both routes and are still not where you need to be, our pillar guide on when weight loss surgery makes sense walks through how clinicians decide on the next step.

More in The Medications

View all →